Detection of fragments of β2-microglobulin in amyloid fibrils  by Stoppini, Monica et al.
Letters to the Editor 349
cyclophosphamide cannot be recommended, we suggest
Detection of fragments ofthat there is available evidence to support the use of
dipyridamole and low-dose warfarin. This regimen has
b2-microglobulin inbeen shown to be safe and its use as long-term therapy
in patients with IgA nephropathy with poor prognostic
amyloid fibrilsindices can slow the rate of decline in renal function and
progression to ESRD.
To the Editor: A major controversy regarding dialysis
related amyloidosis (DRA) is about the presence and
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Table 1. b2-microglobulin isoforms identified by N-terminal amino acid sequence in amyloid deposits from six patients
Carpal tunnel Femoral head
Patients’ names (abbreviations) Voga Igna Maga Gria Coma Sala
b2M full length IQRTPKIQVYSRH 73% 70% 90% 69% 66% 60%
Fragment 7–99 IQVYSRHPAENG 20% 10% 26% 21% 19%
Fragment 11–99 SRHPAENGKSNF 3% 30% 4% 13% 5%
Fragment 20–99 SNFLNCYVSGFH 4% 1% 16%
Yield of first PTH-Ile pmol 25 15 10 1400 1100 1100
The percentage of different isoforms is calculated on the basis of phenylthiohydantoin-amino acid (PTH-AA) yield. The analysis was performed with an HPG1000A
protein sequenator as previously described [3].
a Abbreviated patients’ names
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